Chin N X, Gu J W, Yu K W, Zhang Y X, Neu H C
Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York 10032.
Antimicrob Agents Chemother. 1991 Mar;35(3):567-71. doi: 10.1128/AAC.35.3.567.
Sparfloxacin, a new fluoroquinolone, inhibited the majority of members of the family Enterobacteriaceae at less than or equal to 1 microgram/ml. It was less active than ciprofloxacin but more active than ofloxacin. Against Pseudomonas aeruginosa, it was less active than ciprofloxacin but twofold more active than ofloxacin. It inhibited Staphylococcus aureus and most Streptococcus pneumoniae and Streptococcus pyogenes isolates at 0.25 micrograms/ml, whereas ciprofloxacin and ofloxacin inhibited these isolates at 2 micrograms/ml. Bacteroides fragilis was inhibited by less than or equal to 2 micrograms/ml. Sparfloxacin was less active at an acidic pH and in the presence of Mg2+. Resistance to sparfloxacin was produced by repeated exposure, although the frequency of single-step mutants was less than 10(-9).
司帕沙星是一种新型氟喹诺酮类药物，对大多数肠杆菌科细菌的抑菌浓度小于或等于1微克/毫升。其活性低于环丙沙星，但高于氧氟沙星。对铜绿假单胞菌，其活性低于环丙沙星，但比氧氟沙星高两倍。它对金黄色葡萄球菌以及大多数肺炎链球菌和化脓性链球菌分离株的抑菌浓度为0.25微克/毫升，而环丙沙星和氧氟沙星对这些分离株的抑菌浓度为2微克/毫升。脆弱拟杆菌对其抑菌浓度小于或等于2微克/毫升。司帕沙星在酸性pH值条件下以及存在镁离子时活性较低。反复接触可产生对司帕沙星的耐药性，尽管单步突变的频率小于10^(-9)。
